FDA Oncology Announcements

HIF-2a inhibitor × Clear all

3 Announcements

FDA approves belzutifan for pheochromocytoma or paraganglioma

Trial: MK-6482-015
Drug: Welireg (belzutifan) · HIF-2a inhibitor
Conditions: CNSEndocrine

FDA approves belzutifan for advanced renal cell carcinoma

Drug: Welireg (belzutifan) · HIF-2a inhibitor
Condition: Genitourinary

FDA approves belzutifan for cancers associated with von Hippel-Lindau disease

Trial: MK-6482-004
Drug: Welireg (belzutifan) · HIF-2a inhibitor
Conditions: EndocrineGastrointestinalGenitourinaryNET